• Explore /
  • Poster
  • / Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.

Antitumor activity of sunvozertinib in NSCLC patients with EGFR Exon20 insertion mutations after platinum and anti-PD(L)1 treatment failures.

Abstract Poster

Authors

null

Pasi A. Janne

Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA

Pasi A. Janne , Mengzhao Wang , D. Ross Camidge , Paul Mitchell , Jian Fang , Weiqi Nian , Chao-Hua Chiu , Jianying Zhou , Yanqiu Zhao , Wu-Chou Su , Tsung-Ying Yang , Viola Weijia Zhu , Michael Millward , Yun Fan , Wen-Tsung Huang , Ying Cheng , Liyan Jiang , Daniel Brungs , Li Zheng , James Chih-Hsin Yang

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Lung Cancer—Non-Small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

NCT03974022

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 9015)

DOI

10.1200/JCO.2022.40.16_suppl.9015

Abstract #

9015

Poster Bd #

3

Abstract Disclosures

Similar Posters

First Author: Yan Xu

First Author: James Chih-Hsin Yang

First Author: Jonathan N. Priantti

First Author: Helena Alexandra Yu